Palvella Therapeutics, Inc. Revenue from Contract with Customer, Including Assessed Tax
Palvella Therapeutics, Inc. (PVLA) reported Revenue from Contract with Customer, Including Assessed Tax of $0 for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2024-11-13
- Palvella Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Palvella Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2024-03-31 was $6.00K, a 99.70% decline year-over-year.
- Palvella Therapeutics, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2023-12-31 was $1.05M, a 81.68% decline year-over-year.
- Palvella Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2023 was $38.71M, a 51.99% increase from fiscal 2022.
- Palvella Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2022 was $25.47M, a 8.84% decline from fiscal 2021.
- Palvella Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2021 was $27.94M, a 16.85% increase from fiscal 2020.
- Palvella Therapeutics, Inc. revenue from contract with customer, including assessed tax for fiscal 2020 was $23.91M, a 25.43% decline from fiscal 2019.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $6.00K 10-Q · filed 2024-11-13 | $1.05M derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 | $6.00K 10-Q · filed 2024-08-14 | $1.05M derived: sum of 3 quarters · filed 2024-08-14 | $16.62M derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-03-31 | $6.00K 10-Q · filed 2024-05-15 | $1.05M derived: sum of 2 quarters · filed 2024-05-15 | $16.62M derived: sum of 3 quarters · filed 2024-11-13 | $36.71M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $16.61M derived: sum of 2 quarters · filed 2024-11-13 | $36.70M derived: sum of 3 quarters · filed 2024-11-13 | $38.71M 10-K · filed 2024-03-29 |
| 2023-09-30 | $15.57M 10-Q · filed 2024-11-13 | $35.66M derived: sum of 2 quarters · filed 2024-11-13 | $37.66M 10-Q · filed 2024-11-13 | $43.37M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $20.09M 10-Q · filed 2024-08-14 | $22.10M 10-Q · filed 2024-08-14 | $27.80M derived: sum of 3 quarters · filed 2024-08-14 | $32.92M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $2.01M 10-Q · filed 2024-05-15 | $7.72M derived: sum of 2 quarters · filed 2024-05-15 | $12.83M derived: sum of 3 quarters · filed 2024-05-15 | $16.30M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $5.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $10.82M derived: sum of 2 quarters · filed 2024-03-29 | $14.29M derived: sum of 3 quarters · filed 2024-03-29 | $25.47M 10-K · filed 2024-03-29 |
| 2022-09-30 | $5.11M 10-Q · filed 2023-11-14 | $8.58M derived: sum of 2 quarters · filed 2023-11-14 | $19.76M 10-Q · filed 2023-11-14 | $27.51M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $3.47M 10-Q · filed 2023-08-10 | $14.65M 10-Q · filed 2023-08-10 | $22.40M derived: sum of 3 quarters · filed 2023-08-10 | $25.18M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $11.18M 10-Q · filed 2023-05-11 | $18.93M derived: sum of 2 quarters · filed 2023-05-11 | $21.71M derived: sum of 3 quarters · filed 2023-05-11 | $24.25M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $7.75M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $10.53M derived: sum of 2 quarters · filed 2023-03-31 | $13.07M derived: sum of 3 quarters · filed 2023-03-31 | $27.94M 10-K · filed 2023-03-31 |
| 2021-09-30 | $2.78M 10-Q · filed 2022-11-04 | $5.32M derived: sum of 2 quarters · filed 2022-11-04 | $20.19M 10-Q · filed 2022-11-04 | $21.71M derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-06-30 | $2.54M 10-Q · filed 2022-08-04 | $17.41M 10-Q · filed 2022-08-04 | $18.92M derived: sum of 3 quarters · filed 2022-08-04 | $21.50M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $14.87M 10-Q · filed 2022-05-11 | $16.38M derived: sum of 2 quarters · filed 2022-05-11 | $18.96M derived: sum of 3 quarters · filed 2022-05-11 | $29.89M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | $1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-02 | $4.10M derived: sum of 2 quarters · filed 2022-03-02 | $15.03M derived: sum of 3 quarters · filed 2022-03-02 | $23.91M 10-K · filed 2022-03-02 |
| 2020-09-30 | $2.58M 10-Q · filed 2021-11-02 | $13.51M derived: sum of 2 quarters · filed 2021-11-02 | $22.39M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $10.93M 10-Q · filed 2021-08-05 | $19.82M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $8.88M 10-Q · filed 2021-05-17 | |||
| 2019-12-31 | $32.06M 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |